Paper

Paper

Changelog Terms Privacy Issues Docs Support Foundation About

Phase 2 Open-Label Study of Sacituzumab Govitecan as Seco... | ResearchHub

Paper

Paper

Changelog Terms Privacy Issues Docs Support Foundation About

Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03

0

Authors

Afshin Dowlati

Afshin Dowlati•Anne Chiang•Saiama Waqar

Published

January 1, 2025

Abstract

The phase 2 TROPiCS-03 study evaluated the efficacy/safety of sacituzumab govitecan (SG) as second-line treatment in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC).

Supporters

Support the authors with ResearchCoin

Journal

Journal of Thoracic Oncology

Topics

Cancer Oncology

DOI

10.1016/j.jtho.2024.12.028

License

Supporters

Support the authors with ResearchCoin

Journal

Journal of Thoracic Oncology

Topics

Cancer Oncology

DOI

10.1016/j.jtho.2024.12.028

License